

Immunocore touts first solid tumour survival benefit



Madeleine Armstrong

The next question for Immunocore is whether yesterday's promising data with its soluble T-cell receptor project tebentafusp will [allow the company to float at a decent valuation](#). The company claims its pivotal trial win in uveal melanoma represents the first survival benefit for any TCR therapeutic or any bispecific in a solid tumour. The [IMCgp100-202 trial](#), which compared tebentafusp against investigator's choice in metastatic disease, met its primary endpoint of overall survival – although the data are not yet mature, estimated one-year OS was 73% with tebentafusp versus 58% for investigator's choice, which included Keytruda, Yervoy and dacarbazine chemo. [Checkpoint inhibitors are not usually effective in this rare and aggressive form of eye cancer](#); the median survival after metastasis is around a year. Tebentafusp comprises a soluble TCR targeting gp100, the idea being that it recruits a patient's T cells to the cancerous cells. [Immunocore's sister company Adaptimmune](#) is taking a more typical TCR approach, as an adoptive cell therapy, and reported phase I data last week with its Mage A4-targeting project ADP-A2M4 in synovial sarcoma.

Selected data with T-cell receptor projects in solid tumours

Project	Company	Study	Indication	Data
Tebentafusp (IMCgp100)	Immunocore	IMCgp100-202, NCT03070392	Uveal melanoma	Nov 2020: OS HR 0.51, p<0.0001 1-yr OS 73% tebentafusp vs 58% investigator's choice*
		IMCgp100-102, NCT02570308		Asco 2018: ORR 18%, 1-yr OS 74%
ADP-A2M4	Adaptimmune	ADP-A2M4, NCT03132922	Synovial sarcoma	CTOS 2020: ORR 44% (7/16), median DoR 28 weeks
			Lung, head & neck	Asco 2020: Response seen in 1 lung & one H&N pt
			Rectal mucosal melanoma	Jan 2020: confirmed PR
ADP-A2M4CD8	Adaptimmune	Surpass, NCT04044859	Lung, gastroesophageal, head & neck and bladder	SITC 2020: ORR 33% (2/6)
ADP-A2AFP	Adaptimmune	Phase I, NCT03132792	Liver cancer	Aug 2020: 1 CR (9 pts treated)

*Kaplan-Meier estimate, data not yet mature. Source: Company releases, [clinicaltrials.gov](#).

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](#)

Evaluate Americas
[+1-617-573-9450](#)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2021 Evaluate Ltd.